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Figure 2: Checklist for Assessing Gene Therapies  
  Yes No Notes 
Clinical Effectiveness 
Surrogate endpoint used □ □ Validation given? 
 
Rare disease □ □ Prevalence _____ 
 
Serious condition □ □  
 
Single-armed trial □ □   Matched historical 
cohort used? 
 
Pediatric population  □ □ Age range _____ 
Reporting of adverse consequences 
and risks  
□ □ 
Size of clinical trial _____ number of patients  
Length of clinical trial _____ duration in months  
Extrapolation to long-term outcomes _____ duration in months 
  
Elements of Value 
  
Quantification  
Severe disease □ □ 
Value to caregivers □ □ 
Insurance value □ □ 
Scientific spillovers □ □ 
   
Lack of alternatives □ □ 




Other Considerations   Notes 
Discounting   
Different discount rates explored □ □ 
Uncertainty   
Alternative payment models □ □ 
explored            
Notes:  
	
	 	
	 	
	
	
	
	 	
	
	
	
	
	
	
	
	
	
	
	 	
	 	
	
	
	
	
	
